Publications by authors named "Hiroto Asano"
Article Synopsis
- Monoamine oxidase B (MAO-B) inhibitors, including selegiline, rasagiline, and safinamide, are commonly prescribed to manage Parkinson's disease (PD), but they have distinct pharmacological profiles.
- A study using the FAERS database revealed specific adverse event (AE) signals associated with these drugs, with unique risks like hypocomplementemia and liver disorders linked to selegiline and a tyramine reaction linked to rasagiline.
- Safinamide showed no AE signal for REM sleep behavior disorder, which might indicate its non-dopaminergic effects could provide certain advantages in PD treatment.
